Literature DB >> 9446647

Redundant and selective roles for erythropoietin receptor tyrosines in erythropoiesis in vivo.

G D Longmore1, Y You, J Molden, K D Liu, A Mikami, S Y Lai, P Pharr, M A Goldsmith.   

Abstract

Cytokine receptors have been shown in cell culture systems to use phosphotyrosine residues as docking sites for certain signal transduction intermediates. Studies using various cellular backgrounds have yielded conflicting information about the importance of such residues. The present studies were undertaken to determine whether or not tyrosine residues within the erythropoietin receptor (EPOR) are essential for biologic activity during hematopoiesis in vivo. A variant of the EPOR was constructed that contains both a substitution (R129C) causing constitutive receptor activation as well as replacement of all eight cytoplasmic tyrosines by phenylalanines (cEPORYF). A comparison between animals exposed to recombinant retroviruses expressing cEPOR and cEPORYF showed that efficient red blood cell (RBC) development in vivo is dependent on the pressence of tyrosine residues in the cytoplasmic domain of the EPOR. In addition, an inefficient EPOR tyrosine independent pathway supporting RBC development was detected. Tyrosine add-back mutants showed that multiple individual tyrosines have the capacity to restore full erythropoietic potential to the EPOR as determined in whole animals. The analysis of primary erythroid progenitors transduced with the various cEPOR tyrosine mutants and tyrosine add-backs showed that only tyrosine 343 (Y1) and tyrosine 479 (Y8) were capable of supporting immature burst-forming unit-erythroid progenitor development. Thus, this receptor is characterized by striking functional redundancy of tyrosines in a biologically relevant context. However, selective tyrosine residues may be uniquely important for early signals supporting erythroid development.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9446647

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of stat signals during red blood cell development.

Authors:  S S Watowich; A Mikami; R A Busche; X Xie; P N Pharr; G D Longmore
Journal:  J Interferon Cytokine Res       Date:  2000-12       Impact factor: 2.607

2.  Control of myeloid-specific integrin alpha Mbeta 2 (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1.

Authors:  Athanasia D Panopoulos; David Bartos; Ling Zhang; Stephanie S Watowich
Journal:  J Biol Chem       Date:  2002-03-11       Impact factor: 5.157

3.  The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis.

Authors:  H Zang; K Sato; H Nakajima; C McKay; P A Ney; J N Ihle
Journal:  EMBO J       Date:  2001-06-15       Impact factor: 11.598

4.  Hematopoietic cell survival signals are elicited through non-tyrosine-containing sequences in the membrane-proximal region of the erythropoietin receptor (EPOR) by a Stat5-dependent pathway.

Authors:  Donghoon Yoon; Stephanie S Watowich
Journal:  Exp Hematol       Date:  2003-12       Impact factor: 3.084

5.  KIT associated intracellular tyrosines play an essential role in EpoR co-signaling.

Authors:  Li Hong; Baskar Ramdas; Jinbiao Chen; Chad Harris; Don M Wojchowski; Reuben Kapur
Journal:  Cell Signal       Date:  2008-04-15       Impact factor: 4.315

6.  Absence of cytokine receptor-dependent specificity in red blood cell differentiation in vivo.

Authors:  M A Goldsmith; A Mikami; Y You; K D Liu; L Thomas; P Pharr; G D Longmore
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

7.  Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway.

Authors:  Ping Fu; Xiaohong Jiang; Murat O Arcasoy
Journal:  Biochem Biophys Res Commun       Date:  2009-01-06       Impact factor: 3.575

8.  Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression.

Authors:  Matthew E Hardee; Yiting Cao; Ping Fu; Xiaohong Jiang; Yulin Zhao; Zahid N Rabbani; Zeljko Vujaskovic; Mark W Dewhirst; Murat O Arcasoy
Journal:  PLoS One       Date:  2007-06-20       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.